Sector consensus Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
NYSE
00:00:00 18/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.880 USD | +6.67% |
|
-3.68% | +4.73% |
| 08-19 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 08-14 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 12.29 | +355.03% | 14 | ||||||
| 688.17 | +27.82% | 23 | ||||||
| 277.94 | +3.39% | 18 | ||||||
| 251.21 | +28.22% | 20 | ||||||
| 432.8 | +24.34% | 28 | ||||||
| 268,232.21 | +51.37% | 22 | ||||||
| 581.83 | -5.61% | 12 | ||||||
| 270.95 | +26.23% | 20 | ||||||
| 72.24 | -3.29% | 14 | ||||||
| 185.56 | +6.68% | 16 | ||||||
| 282.43 | +3.3% | 14 | ||||||
| 68.18 | -2.56% | 17 | ||||||
| 70.73 | -2.22% | 11 | ||||||
| 50.57 | +17.2% | 11 | ||||||
| 137.98 | +52.54% | 7 | ||||||
| 137.73 | +18.39% | 22 | ||||||
| 174.69 | +22.3% | 13 | ||||||
| 3.908 | -5.83% | 7 | ||||||
| 46.27 | +7.85% | 15 | ||||||
| 638.68 | +106.7% | 19 | ||||||
| Average | 13,630.82 | +36.59% | 16 | ||||||
| Weighted average by Cap. | 22,979.91 | +20.75% | 19 |
- Stock Market
- Stocks
- CATX Stock
- Sector Perspective Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
